The role of carbapenems in the treatment of severe nosocomial respiratory tract infections

Bibliography

• Burgess DS, Frei CR. Comparison of beta-lactam regimens for the treatment of Gram negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. J Antimicrob Chemother 2005;56(5):893-8
   PubMed Web of Science ®Google Scholar
• American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
   PubMed Web of Science ®Google Scholar
• Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. Crit Care Med 1999;27(5):887-92
   PubMed Web of Science ®Google Scholar
• Baughman RP, Tapson V, Mcivor A. The diagnosis and treatment challenges in nosocomial pneumonia. Diagn Microbiol Infect Dis 1999;33:131-9
   PubMed Web of Science ®Google Scholar
• Bodmann KF. Current guidelines for the treatment of severe pneumonia and sepsis. Chemotherapy 2005;51:227-33
   PubMed Web of Science ®Google Scholar
• Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infection: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74
   PubMed Web of Science ®Google Scholar
• Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002;122:2183-96
   PubMed Web of Science ®Google Scholar
• Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol 1996;17(8):552-7
   PubMed Web of Science ®Google Scholar
• Combes A, Figliolini C, Trouillet JL, et al. Incidence and outcome of polymicrobial ventilator-associated pneumonia. Chest 2002;121:1618-23
   PubMedGoogle Scholar
• Lynch JP. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 2001;119(2 Suppl):373S-384S
   PubMed Web of Science ®Google Scholar
• Kollef MH, Kollef KE. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results. Chest 2005;128:2706-13
   PubMed Web of Science ®Google Scholar
• Patterson JE. Antibiotic utilization: is there an effect on antimicrobial resistance? Chest 2001;119:426S-430S
   PubMed Web of Science ®Google Scholar
• Craig W. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin N Am 2003;17:479-501
   PubMed Web of Science ®Google Scholar
• Craig W. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96
   PubMed Web of Science ®Google Scholar
• Craig W. Pharmacokinetic/Pharmacodynamic parameters: rationale for antibacterial dosing in mice and men. Clin Infect Dis 1998;26:1-12
   PubMed Web of Science ®Google Scholar
• Dennesen PJ, Van Der Ven A, Kessels AG, et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001;163:1371-5
   PubMed Web of Science ®Google Scholar
• Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. Am J Respir Crit Care Med 2000;162:505-11
   PubMed Web of Science ®Google Scholar
• Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003;31(3):969-70
   PubMedGoogle Scholar
• Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA 2003;290(19):2588-98
   PubMed Web of Science ®Google Scholar
• Sumita Y, Fukasawa M, Okuda T. Affinities of SM-7338 for penicillin binding protein and its release from these proteins in Staphylococcus aureus. Antimicrob Agents Chemother 1990;34(3):484-6
   PubMed Web of Science ®Google Scholar
• Sumita Y, Fuksawa M, Okuda T. Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin binding protein and morphological changes. J Antibiot (Tokyo) 1990;43(3):314-20
   PubMed Web of Science ®Google Scholar
• Kitzis MD, Acar JF, Gutmann L. Antibacterial activity of meropenem against Gram negative bacteria with a permeability defect against staphylococci. J Antimicrob Chemother 1989;24(Suppl A):125S-132S
   PubMed Web of Science ®Google Scholar
• Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem–cilastatin. Antimicrob Agents Chemother 1994;38(3):547-57
   PubMed Web of Science ®Google Scholar
• Seiger B, Berman SJ, Geckler R, Farkas S. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Crit Care Med 1997;25(10):1663-70
   PubMedGoogle Scholar
• Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem–cilastatin for treatment of nosocomial pneumonia in intensive care unit patients; a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003;47(11):3442-7
   PubMed Web of Science ®Google Scholar
• Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem–cilastatin and pipercillin–tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998;42(11):2966-72
   PubMed Web of Science ®Google Scholar
• Torres A, Bauer TT, Leon-Gill C, et al. Treatment of severe nosocomial pneumonia: a prospective randomized comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax 2000;55:1033-9
   PubMed Web of Science ®Google Scholar
• Schmitt DV, Leitner E, Welte T, Lode H. Pipercillin/Tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia – a double blind prospective multicentre study. Infection 2006;34:127-34
   PubMed Web of Science ®Google Scholar
• Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994;38(6):1309-13
   PubMed Web of Science ®Google Scholar
• Joshi M, Metzler M, Mccarthy M, et al. Comparision of pipercillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia. Respir Med 2006;100:1154-565
   Google Scholar
• West M, Boulanger B, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003;23(2):485-505
   Google Scholar
• Hartenauer U, Weilemann LS, Bodmann KF, et al. Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias. J Hosp Infect 1990;15:61-4
   PubMedGoogle Scholar
• Colardyn F, Faulkner KL. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J Antimicrob Chemother 1996;38:523-37
   PubMed Web of Science ®Google Scholar
• Garau J, Blanquer J, Cobo L, et al. Prospective, randomized, multicentre study of meropenem versus imipenem/cilastatin as empiric montherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis 1997;16:789-96
   PubMed Web of Science ®Google Scholar
• Alvarez-Lerma F, Santos FM, De Castro J, et al. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001;13(1):70-81
   PubMed Web of Science ®Google Scholar
• Santos SS, Machado FR, Kiffer CR, Barone AA. Treatment of nosocomial pneumonia: an experience with meropenem. Braz J Infect Dis 2001;5(3):124-9
   PubMedGoogle Scholar
• Berman SJ, Fogarty CM, Fabian T, et al. Meropenem monotherapy for the treatment of hospital-acquired pneumonia: results of a multicenter trial. J Chemother 2004;16(4):362-71
   PubMed Web of Science ®Google Scholar
• Mouton YJ, Beuscart C; Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995;36(Suppl A):145-56
   PubMed Web of Science ®Google Scholar
• Jaspers C, Kieft H, Speelberg B, et al. Meropenem versus cefuroxime plus gentamicin for treatment for serious infections in elderly patients. Antimicrob Agents Chemother 1998;42:1233-8
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Fasce R, et al. Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. J Antimicrob Chemother 2007;60(2):433-5
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72
   PubMed Web of Science ®Google Scholar
• Burkhardt O, Derendorf H, Welte T. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother 2007;8(2):237-56
   PubMed Web of Science ®Google Scholar
• Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003;52:331-44
   PubMed Web of Science ®Google Scholar
• Doribax® (doripenem) [package insert]. Raritan, New Jersey: Ortho-McNeil, Inc., 2007
   Google Scholar
• Lister PD. Carbapenems in the USA: focus on doripenem. Expert Rev Anti Infect Ther 2007;5:793-809
   Google Scholar
• Anderson DL. Doripenem. Drugs Today (Barc) 2006;42(6):399-404
   PubMed Web of Science ®Google Scholar
• Jones RN, Huynh HK, Biedenbach, et al. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004;54:144-54
   PubMed Web of Science ®Google Scholar
• Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005;52:71-4
   PubMed Web of Science ®Google Scholar
• Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004;48(8):3136-40
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Sader HS, Strabala PA, Jones RA. Activity of doripenem tested against an international collection of ESBL- and AmpC-producing Enterobacteriaceae. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA; 2006
   Google Scholar
• Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect Dis 2005;11:974-84
   Google Scholar
• Sakyo S, Tomita H, Tanimoto K, et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J Antibiot 2006;59(4):220-8
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004;48(8):3086-92
   PubMed Web of Science ®Google Scholar
• Huynh HK, Biedenbach DJ, Jones RN. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn Microbiol Infect Dis 2006;55(3):241-3
   PubMed Web of Science ®Google Scholar
• Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5000 patients treated with meropenem. Scand J Infect Dis 1999;31(1):3-10
   PubMed Web of Science ®Google Scholar
• Norrby SR. Carbapenems in serious infections: a risk–benefit assessment. Drug Safety 2000;22(3):191-4
   PubMed Web of Science ®Google Scholar
• Norrby SR. Neurotoxicity of carbapenem antibiotics: consequence for their use in bacterial meningitis. J Antimicrob Chemother 2000;45:5-7
   PubMed Web of Science ®Google Scholar
• Prescott WA Jr, Depestel DD, Ellis JJ, Regal RE. Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy. Clin Infect Dis 2004;38:1102-7
   PubMed Web of Science ®Google Scholar
• Teppler H, Gesser RM, Friedland IR, et al. Safety and tolerability of ertapenem. J Antimicrob Chemother 2004;53(Suppl 2):75-81
   Web of Science ®Google Scholar
• Osson C, Cunningham S. Additional information concerning the comparison of imipenem and meropenem. Can J Infect Dis 1998;9(5):322-4
   Google Scholar
• Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988;84(5):911-8
   PubMed Web of Science ®Google Scholar
• Saidel-Odes L, Borer A, Reisenberg K, et al. History of cerebrovascular events: a relative contraindication to ertapenem treatment. Clin Infect Dis 2006;43:262-3
   PubMedGoogle Scholar
• Seto AH, Song JC, Guest SS. Ertapenem-associated seizures in a peritoneal dialysis patient. Ann Pharmacother 2005;39(2):352-6
   PubMed Web of Science ®Google Scholar
• Rolston KV, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283-91
   PubMed Web of Science ®Google Scholar
• Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994;38(6):1309-13
   PubMed Web of Science ®Google Scholar
• Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5000 patients treated with meropenem. Scand J Infect Dis 1999;31(1):3-10
   PubMed Web of Science ®Google Scholar
• Kollef MH. Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of carbapenems. Respir Care 2004;49(12):1530-41
   PubMedGoogle Scholar
• Norrby SR. Carbapenems in serious infections: a risk–benefit assessment. Drug Safety 2000;22(3):191-4
   PubMed Web of Science ®Google Scholar
• Klugman KP, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Antimicrob Agents Chemother 1995;39:1140-6
   PubMed Web of Science ®Google Scholar
• Patel JB, Giles RE. Meropenem: evidence of lack of proconvulsive tendency in mice. J Antimicrob Chemother 1989;24(Suppl A):307S-09S
   PubMedGoogle Scholar
• Guglielmo BJ, Jacobs RA. Impact of dosage-monitoring system on frequency of seizures associated with imipenem–cilastatin. Am J Health Syst Pharm 1996;53(17):2097-8
   PubMedGoogle Scholar
• Abel SR, Guba EA. Evaluation of an imipenem/cilastatin target drug program. DICP 1991;25:348-50
   PubMedGoogle Scholar
• Job ML, Dretler RH. Seizure activity with imipenem therapy: incidence and risk factors. DICP 1990;24(5):467-9
   PubMedGoogle Scholar
• Wong VK, Wright HT Jr, Ross LA, et al. Imipenem/Cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991;10(2):122-5
   PubMed Web of Science ®Google Scholar
• Hikida M, Masukawa Y, Nishiki K, Inomata N. Low neurotoxicity of LJC 10,627, a novel 1 beta-methyl carbapenem antibiotic: inhibition of gamma-aminobutyric acidA, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats. Antimicrob Agents Chemother 1993;37:199-202
   PubMedGoogle Scholar
• Sunagawa M, Matsumura H, Sumita Y, Nouda H. Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain. J Antibiot (Tokyo) 1995;48:408-16
   PubMed Web of Science ®Google Scholar
• Horiuchi M, Kimura M, Tokumura M, et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology 2006;222(1/2):114-24
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85
   PubMedGoogle Scholar
• Aronoff SC, Shlaes DM. Factors that influence the evolution of beta-lactam resistance in beta-lactamase-inducible strains of Enterobacter cloacae and Pseudomonas aeruginosa. J Infect Dis 1987;155(5):936-41
   PubMed Web of Science ®Google Scholar
• Jacoby GA, Munoz-Price L. The new β-lactamases. N Engl J Med 2005;352:380-91
   PubMed Web of Science ®Google Scholar
• Rhomberg PR, Jones RN, Sader HS; Mystic Programme (US) Study Group. Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres. Int J Antimicrob Agents 2004;23:52-9
   PubMed Web of Science ®Google Scholar
• Macgowan AP, Bowker KE. Continuous infusion of β-lactam antibiotics. Clin Pharmacokinet 1998;35(5):391-402
   PubMed Web of Science ®Google Scholar
• Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among Gram-negative bacilli in US intensive care units. JAMA 2003;289:885-8
   PubMed Web of Science ®Google Scholar
• Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006;12(9):826-36
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006;64:7-15
   PubMed Web of Science ®Google Scholar
• Lolans K, Queenan AM, Bush K, et al. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-β-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother 2005;49(8):3538-40
   PubMed Web of Science ®Google Scholar
• Pournaras S, Markogiannakis A, Ikonomidis A, et al. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. J Antimicrob Chemother 2006;57:557-61
   PubMed Web of Science ®Google Scholar
• Hanson ND, Hossain A, Buck L, et al. First occurrence of a Pseudomonas aeruginosa isolate in the United States producing an IMP metallo-beta-lactamase, IMP-18. Antimicrob Agents Chemother 2006;50(6):2272-3
   PubMed Web of Science ®Google Scholar
• Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006;12:826-36
   PubMed Web of Science ®Google Scholar
• Köhler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Anitmicrob Agents Chemother 1999;43(2):424-7
   PubMed Web of Science ®Google Scholar
• Paterson DL. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am J Med 2006;119(6A):S20-8
   PubMed Web of Science ®Google Scholar
• Jones RN, Biedenbach DJ, Gales AC. Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA,(1997) –2000). Int J Antimicrob Agents 2003;21:1-7
   PubMed Web of Science ®Google Scholar
• Héritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49(8):3198-202
   PubMed Web of Science ®Google Scholar
• Yang K, Guglielmo BJ. Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms. Ann Pharmacother 2007;41:1427-35
   PubMed Web of Science ®Google Scholar
• Karas JA, Pillay DG, Muckart D, Sturm AW. Treatment failure due to extended spectrum beta-lactamase. J Antimicrob Chemother 1996;37:203-4
   PubMed Web of Science ®Google Scholar
• Performance standards for antimicrobial susceptibility testing; 16th Informational Supplement. M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute; 2006
   Google Scholar
• Raveh D, Yinnon AM, Broide E, Rudensky B. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin–tazobactam with and without clavulanic acid. Chemotherapy 2007;53(3):185-9
   PubMedGoogle Scholar
• Pfaller MA, Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998–2004). Diagn Microbiol Infect Dis 2006;56(1):63-8
   PubMed Web of Science ®Google Scholar
• Song W, Moland ES, Hanson ND, et al. Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J Clin Microbiol 2005;43(9):4891-4
   PubMedGoogle Scholar
• Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics–Pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob Agents Chemother 2003;47(5):1643-6
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Bhavani SM, Rubino CM, et al. Pharmacokinetics–Pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007;44(1):79-86
   PubMed Web of Science ®Google Scholar
• Den Hollander JG, Fuursted K, Verurgh HA, Mouton JW. Duration and clinical relevance of post-antibiotic effect in relation to the dosing interval. Antimicrob Agents Chemother 1998;42(4):749-54
   PubMedGoogle Scholar
• Den Hollander JG, Mouton JW, Van Goor MP, et al. Alteration of post-antibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996;40(3):784-6
   PubMedGoogle Scholar
• Hanberger H, Nilsson LE, Nilsson M, Maller R. Post-antibiotic effect of beta-lactam antibiotics on Gram-negative bacteria in relation to morphology, initial killing and MIC. Eur J Clin Microbiol Infect Dis 1991;10(11):927-34
   PubMed Web of Science ®Google Scholar
• Drusano GL, Hutchinson M. The pharmacokinetics of meropenem. Scand J Infect Dis 1995;96(Suppl):11S-6S
   Google Scholar
• Krueger WA, Bulitta J, Kinzig-Schippers M, et al. Evaluation of Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 2005;49(5):1881-9
   PubMed Web of Science ®Google Scholar
• Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003;43:1116-23
   PubMed Web of Science ®Google Scholar
• Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother 2005;49(1):461-3
   PubMed Web of Science ®Google Scholar
• Bhavani SM, Hammel JP, Cirincione BB, et al. Use of pharmacokinetic–pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005;49(9):3944-7
   PubMedGoogle Scholar
• Lorente L, Lorenzo L, Martin MM, et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to Gram-negative bacilli. Ann Pharmacother 2006;40:219-23
   PubMed Web of Science ®Google Scholar
• Rea-Neto A, Niederman M, Prokocimer P, et al. Efficacy and safety of intravenous doripenem vs piperacillin/tazobactam in nosocomial pneumonia. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago; 18 September 2007
   Google Scholar
• Chastre J, Wunderink R, Prockocimer P, et al. Efficacy and safety of intravenous doripenem vs imipenem for ventilator-associated pneumonia. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago; 18 September 2007
   Google Scholar
• Viaene E, Chanteux H, Servais H, et al. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care unit). Antimicrob Agents Chemother 2002;46:2327-32
   PubMed Web of Science ®Google Scholar
• Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther 2004;26:493-501
   PubMed Web of Science ®Google Scholar
• Psathas P, Kuzmission A, Ikeda K, Yasuo S. Stability of doripenem for injection (500 mg) in representative infusion fluids and containers. Presented at the American Society of Hospital Pharmacists Summer Meeting; San Francisco; 22 July 2007
   Google Scholar
• Trissel LA, Brammer MK, Chan P, et al. Compatibility of doripenem injection with selected other drugs during simulated y-site co-administration. Presented at the American Society of Hospital Pharmacists Midyear Meeting. Las Vegas; 3 December 2007
   Google Scholar
• Chisholm DR, Deregis RG, Behr DA. Therapeutic efficacy of cefadroxil and cephalexin for pneumonia in a rat test model. Antimicrob Agents Chemother 1986;30(1):105-9
   PubMedGoogle Scholar
• Vallée E, Azoulay-Dupuis E, Pocidalo JJ, Bergogne-Bérézin E. Pharmacokinetics of four fluoroquinolones in an animal model of infected lung. J Antimicrob Chemother 1991;28(Suppl C):39-44
   PubMedGoogle Scholar
• Azoulay-Dupuis E, Vallée E, Bedos JP, et al. Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia. Antimicrob Agents Chemother 1991;35(6):1024-8
   PubMed Web of Science ®Google Scholar
• Aoun M, Klastersky J. Drug treatment of pneumonia in the hospital. What are the choices? Drugs 1991;42(6):962-73
   PubMedGoogle Scholar
• Conte JE Jr, Goldn JA, Kelley MG, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int J Antimicrob Agents 2005;26(6):449-56
   PubMed Web of Science ®Google Scholar
• Tomaselli F, Maiera A, Matzi V, et al. Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Antimicrob Agents Chemother 2004;48(6):2228-32
   PubMed Web of Science ®Google Scholar
• Allegranzi B, Cazzadori A, Di Perri G, et al. Concentrations of single-dose meropenem (1 g iv) in bronchoalveolar lavage and epithelial lining fluid. J Antimicrob Chemother 2000;46:319-22
   PubMedGoogle Scholar
• Muller-Serieys C, Bergogne-Berezin E, Rowan C, Dombret MC. Imipenem penetration into bronchial secretions. J Antimicrob Chemother 1987;20(4):618-9
   PubMedGoogle Scholar
• Boselli E, Breilh D, Saux MC, et al. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med 2006;32(12):2059-62
   PubMed Web of Science ®Google Scholar
• Burkhardt O, Majcher-Peszynska J, Borner K, et al. Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery. J Clin Pharmacol 2005;45(6):659-65
   PubMed Web of Science ®Google Scholar
• Hori T, Nakano M, Kimura Y, Murakami K. Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. In Vivo 2006;20(1):91-6
   PubMed Web of Science ®Google Scholar
• Tegeder I, Schmidko A, Bräutigam L, et al. Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 2002;71(5):325-33
   PubMed Web of Science ®Google Scholar
• Dailly E, Kergueris MF, Pannier M, et al. Population pharmacokinetics of imipenem in burn patients. Fundam Clin Pharmacol 2003;17(6):645-50
   PubMedGoogle Scholar
• King JH, Kailath EJ, Hrdy DB. Successful use of higher-than-recommended dosage of imipenem in Pseudomonas aeruginosa endocarditis. Ann Pharmacother 1992;26(5):639-41
   PubMedGoogle Scholar
• Tunkel AR, Hartman BJ, Kaplan SL. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39(9):1267-84
   PubMed Web of Science ®Google Scholar
• Thalhammer F, Traunmüller F, El Menyawi I, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999;43(4):523-7
   PubMed Web of Science ®Google Scholar